The Impacts of Drug Price Regulations in China

Abstract

To lower pharmaceutical expenditure, the Chinese government has replaced the Fixed Percent Markup (FPM) policy with the policies of the Separation of Outpatient Pharmacies from Hospitals (SOPH) and the Zero Markup Drug (ZMD). We build a multistage game theoretic model comprising a hospital and a drugstore to analyze the policies’ impacts on the providers’ drug selection and pricing behaviors. By comparing the equilibrium outcomes, we draw the following conclusions: (i) FPM, especially for one imposing a strict margin ceiling, actually induces an expensive prescription given patients’ great compliance. (ii) Both SOPH and ZMD can conditionally lower patients’ expenditure, and their performances rely on the hospital’s selection. (iii) A proper rate of insurance coverage and a removal of drug rebate are helpful to improve the policies’ performance.

Keywords

Drug price regulations / patients’ expenditure / healthcare reform / game theory

References

[1] Bardey D, Canta C, Lozachmeur J M. The regulation of health care providers’ payments when horizontal and vertical differentiation matter. Journal of Health Economics, 2012, 31(5): 691-704.

[2] Brekke K R, Königbauer I, Straume O R. Reference pricing of pharmaceuticals. Journal of Health Economics, 2007, 26(3): 613-642.

[3] Brekke K R, Siciliani L, Straume O R. Hospital competition and quality with regulated prices. The Scandinavian Journal of Economics, 2011, 113(2): 444-469.

[4] Cramer J A, Roy A, Burrell A, Fairchild C J, Fuldeore M J, Ollendorf D A, Wong P K. Medication compliance and persistence: Terminology and definitions. Value in Health, 2008, 11(1): 44-47.

[5] Currie J, Lin W, Zhang W. Patient knowledge and antibiotic abuse: Evidence from an audit study in China. Journal of Health Economics, 2011, 30(5): 933-949.

[6] Eggleston K. Prescribing institutions: Explaining the evolution of physician dispensing. Journal of Institutional Economics, 2012, 8(02): 247-270.

[7] Eggleston K (2012). Health care for 1.3 billion: An overview of China’s health system. Working Paper Stanford University.

[8] Fenton W S, Blyler C R, Heinssen R K. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 1997, 23(4): 637-651.

[9] He Z, Zhou J. Can zero-markup policy for drug sales in public hospitals resolve the problem of ‘seeing a doctor is too expensive’ in China? A case study of four municipal general tertiary hospitals at H City in Z Province. Journal of Chinese Governance, 2017, 2(3): 329-342.

[10] Ho P M, Bryson C L, Rumsfeld J S. Medication adherence its importance in cardiovascular outcomes. Circulation, 2009, 119(23): 3028-3035.

[11] Hong Kong Medical Association (1999). Survey revealed patients upheld their own choice of where to get their prescribed medicine filled. http://www.legco.gov.hk/yr98-99/english/panels/hs/papers/2904e01.pdf

[12] Hu S. Financing, pricing and utilisation of pharmaceuticals in China: The road to reform, 2010, Beijing: The World Bank

[13] Kim H J, Ruger J P. Pharmaceutical reform in South Korea and the lessons it provides. Health Affairs, 2008, 27(4): 260-269.

[14] Li X, Lu J, Hu S, Cheng K K, De Maeseneer J, Meng Q, Mossialos E, Xu D, Yip W, Zhang H, Krumholz H M, Jiang L, Hu S. The primary health-care system in China. The Lancet, 2017, 390(10112): 2584-2594.

[15] Lim D, Emery J, Lewis J, Sunderland V B. A systematic review of the literature comparing the practices of dispensing and non-dispensing doctors. Health Policy, 2009, 92(1): 1-9.

[16] Liu Y M, Yang Y H K, Hsieh C R. Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan. Journal of Health Economics, 2009, 28(2): 341-349.

[17] Qin B (2015). Sustainable Development in Rural China: Field Survey and Sino-Japan Comparative Analysis. Springer. https://books.google.com.

[18] Sun Q, Santoro M A, Meng Q, Liu C, Eggleston K. Pharmaceutical policy in China. Health Affairs, 2008, 27(4): 1042-1050.

[19] Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: Three decades of research: A comprehensive review. Journal of Clinical Pharmacy and Therapeutics, 2001, 26(5): 331-342.

[20] Yang C, Shen Q, Cai W, Zhu W, Li Z, Wu L, Fang Y. Impact of the zero-markup drug policy on hospitalisation expenditure in western rural China: An interrupted time series analysis. Tropical Medicine & International Health, 2017, 22(2): 180-186.

[21] Yi H, Miller G, Zhang L, Li S, Rozelle S. Intended and unintended consequences of China’s zero markup drug policy. Health Affairs, 2015, 34(8): 1391-1398.

[22] Yip W C M, Hsiao W C, Chen W, Hu S, Ma J, Maynard A. Early appraisal of China’s huge and complex health-care reforms. The Lancet, 2012, 379(9818): 833-842.

[23] Zhang W Y, Li Y R, Li Y J, Li X Q, Zhao W G, Lu R Z. A cross-sectional analysis of prescription and stakeholder surveys following essential medicine reform in Guangdong Province, China. BMC Health Services Research, 2015, 15(1): 98.

[24] Zhang Y, Guan X, Shi L (2016). A retrospective study on hospital pharmacy trusteeship in China. Chinese Medicine (5): 491–495.

[25] Zhou Z, Su Y, Campbell B, Zhou Z, Gao J, Yu Q, Pan Y. The impact of China’s Zero-Markup Drug Policy on county hospital revenue and government subsidy levels. Journal of Asian Public Policy, 2015, 8(1): 102-116.

[26] Zhou Z, Su Y, Campbell B, Zhou Z, Gao J, Yu Q, Pan Y. The financial impact of the ‘zero-markup policy for essential drugs’ on patients in county hospitals in western rural China. PloS One, 2015, 10(3): e0121630.